Comparing two chemotherapy approaches for unresectable colorectal cancer with liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of FOLFOX hepatic artery infusion chemotherapy combined with intravenous irinotecan, with or without bevacizumab, against systemic intravenous FOLFOXIRI with or without bevacizumab in patients with initially unresectable RAS-mutated colorectal cancer that has spread to the liver. The study aims to determine the objective remission rate and assess various secondary outcomes such as surgical resection rates and overall survival. Patients will receive treatment every 14 days for a maximum of 12 cycles, depending on their response and tolerance to the therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed colorectal adenocarcinoma
2. Imaging or pathological confirmation of liver metastases
3. The multidisciplinary team determined that the liver metastases were unresectable, defined as (i) ≥5 metastases; (ii) inability to perform R0 resection; (iii) insufficient volume of liver expected to remain after resection; (iv) failure to preserve all 3 hepatic veins after resection, failure to ensure that blood flow to and from the liver and bile ducts can be preserved, and failure to preserve 2 adjacent liver segments. If any of the above criteria are met, it can be considered as initially unresectable liver metastases.
4. Patients with mutated RAS and BrafV600E
5. No previous treatment for liver metastases, including chemotherapy, surgery, radiotherapy, transarterial chemoembolization (TACE) and targeted therapy
6. No extrahepatic metastases confirmed by CT, MRI, or PET/CT (if necessary) (consider enrollment if there is a lung or lymph node lesion less than 10 mm and metastases are difficult to identify)
7. Normal hematological function (platelets \>90×109/L; white blood cells \>3×109/L; neutrophils \>1.5×109/L)
8. Serum bilirubin ≤ 1.5 times the upper limit of normal value (ULN), transaminases ≤ 5 times ULN
9. No ascites, normal coagulation function, albumin ≥35g/L
10. Liver function Child-Push grade A
11. Serum creatinine less than upper limit of normal (ULN) or calculated creatinine clearance \>50 ml/min (using Cockcroft-Gault formula)
12. ECOG score 0-1
13. Life expectancy \> 3 months
14. Signed written informed consent

Exclusion Criteria (Patients meeting any of the following criteria will be excluded from the study):

1. Presence of any extrahepatic metastases and/or primary tumor not amenable to radical surgical resection
2. Development of liver metastases within 1 year after completion of adjuvant chemotherapy with FOLFOX or XELOX
3. Severe arterial embolism or ascites
4. Bleeding tendency or coagulation disorder
5. Hypertensive crisis or hypertensive encephalopathy
6. Severe uncontrolled systemic complications such as infections or diabetes mellitus
7. Clinically significant cardiovascular disease such as cerebrovascular accident (within 6 months prior to enrollment), myocardial infarction (within 6 months prior to enrollment), uncontrolled hypertension despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA class 2-4), arrhythmias requiring medication
8. History or physical examination revealing a central nervous system disease (e.g., primary brain tumor, epilepsy not manageable by standard therapy, presence of brain metastases, or history of stroke)
9. Previous malignancy within the last 5 years (except post-radical surgery basal cell carcinoma of the skin and/or carcinoma in situ of the cervix)
10. Treatment using any investigational drug within the last 28 days prior to the study
11. Any residual toxicity from prior chemotherapy (except alopecia), such as peripheral neuropathy ≥ NCI CTC v3.0 grade 2, will not be considered for treatment with oxaliplatin-containing regimens
12. History of allergy to any of the drugs in the study
13. Women of childbearing potential (\<2 years after last menstruation) or men of childbearing potential who are not using or have refused to use an effective non-hormonal contraceptive (IUD, barrier method combined with spermicidal gel or sterilization) during pregnancy and lactation
14. Unable or unwilling to comply with the study protocol
15. Presence of any other disease, dysfunction due to metastatic lesions, or suspicious medical findings that suggest a possible contraindication to the use of the study drug or that would place the patient at risk of treatment-related complications

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Li Yuhong
• Email: liyh@sysucc.org.cn
• Phone: 020-87342487

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• ctDNA-guided choice of cetuximab versus bevacizumab with trifluridine/tipiracil for RAS/BRAF wild-type metastatic colorectal cancer

  This trial tests whether a ctDNA blood test can help choose cetuximab plus trifluridine/tipiracil versus bevacizumab plus trifluridine/tipiracil for people with RAS/BRAF wild-type metastatic colorectal cancer who have progressed after prior treatments.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07012954

• Comparing two treatments for advanced colorectal cancer

  This study is testing whether a combination of two cancer treatments works better than another combination for people with advanced colorectal cancer that hasn’t responded to other therapies.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06992648

• Oral trifluridine/tipiracil with bevacizumab and sintilimab, with or without targeted radiation, for advanced MSS/pMMR colorectal cancer after two or more prior treatments

  This trial will try oral trifluridine/tipiracil combined with bevacizumab and sintilimab, with or without focused radiation, in people with advanced MSS/pMMR colorectal cancer who have progressed after at least two prior therapies.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06764680

• Second-line treatment for advanced colorectal cancer using new chemotherapy options

  This study is testing a new combination of chemotherapy drugs to see if it can help people with advanced colorectal cancer who haven't had success with their first treatment.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06540326

• Combination immunotherapy and chemotherapy for advanced colorectal cancer

  This study is testing a new treatment for patients with advanced colorectal cancer that combines immunotherapy and chemotherapy to see if it can help them better than current options.

  Recruiting Phase 2 Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Meldola, Forlì Cesena and 1 other locations · NCT06522919

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.